SEC Form 5

FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See [

Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL

OMB Number: 3235-0362 1.0

Instruction 1(b).						OW	NE	RSHI	Ρ	Estimated average burden hours per response: 1.0											
2	4 Transactions		File	d pursuant											<u>. </u>						
1. Name and Address of Reporting Person [*] 2. Issue						Section 30(h) of the Investment Company Act of 1940 Issuer Name and Ticker or Trading Symbol <u>rganogenesis Holdings Inc.</u> [ORGO]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) (First) (Middle) 35 SAWGRASS DRIVE					3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2020									Office belov	er (give titl v)	e	Oth belo		pecify		
(Street) BELLPORT NY			11713	4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) 5. Individual or Joint/Group Filing (Check A Line) Form filed by One Reporting Pers X Form filed by More than One Rep Person									Perso	n						
(City)	(Si																				
			e I - Non-Deriv			1	quire		-					1							
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquir Of (D) (Instr. 3, 4 and			d 5) ´ .			Securities Beneficially Owned at end of Issuer's Fiscal		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Amoun	t	(A) (D)	or	Price		Year (Ins 4)		(Instr.		Ĺ			
Class A Common Stock			12/29/2020			G	G		251,430 ⁽¹⁾		>	\$ <mark>0</mark>		68,543,546		D					
Class A G	12/29/2020			G	G		251,430 ⁽¹⁾		1	\$0.0		68,794,976		6 D							
		Ta	able II - Derivat (e.g., p	tive Sec uts, call										y Owne	d						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. D 8) A (/ Code (Instr. D 8) A (/ C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		f Expi		ate Exercisable and iration Date nth/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5) tr.		9. Numbo derivativ Securitie Beneficia Owned Followin Reported Transact (Instr. 4)	e s ally g	10. Owners Form: Direct (or Indir (I) (Instr	D) ect	Beneficial O) Ownership ect (Instr. 4)		
					(A)) (D)	Date	e rcisable	Expirati Date		Title	Amou or Numb of Share	er								
1. Name ai NUSSI																					
(Last) (First) 35 SAWGRASS DRIVE			(Middle)																		
(Street) BELLPORT		NY	11713																		
(City)		(State)	(Zip)																		
1. Name and Address of Reporting Person [*] Wisdom Starr																					
(Last) 44 WILSON STRE		(First) ET	(Middle)																		
(Street) HARTSDALE		NY	10530																		

Explanation of Responses:

(State)

(Zip)

1. Such shares were previously held by GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the "GN 2016 GRAT"), a member of the Group (as defined below). On December 29, 2020, the GN 2016 GRAT distributed 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to Glenn H. Nussdorf in satisfaction of its annuity obligation and in an exempt transaction pursuant to Rule 16a-13. On December 29, 2020, Glenn H. Nussdorf transferred 251,430 shares of Class A Common Stock of Organogenesis Holdings Inc. to GN 2016 Family Trust u/a/d August 12, 2016 for no consideration. Each of Glenn H. Nussdorf and GN 2016 Family Trust u/a/d August 12, 2016 is a member of the Group.

Remarks:

(City)

Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016 and GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, referred to collectively as the "Controlling Entities", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Controlling Entities with respect to four directors of the Issuer and qualifies the Issuer as a "controlled company" under the Nasdaq listing rules. As a result of the Stockholders' Agreement, the reporting persons may be deemed to be members of a group (the "Group") holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. This is Form 5 No. 2 of 2 filed for the Controlling Entities.

<u>/s/ Stacie S. Aarestad,</u> <u>Attorney-in-Fact</u>

** Signature of Reporting Person Date

02/12/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.